Evidence map›Paper›PMID 33335150›Full record

ArticleScientific reports2020

Targeting oxytocin receptor (Oxtr)-expressing neurons in the lateral septum to restore social novelty in autism spectrum disorder mouse models.

Machi Horiai, Ayano Otsuka, Shizu Hidema, Yuichi Hiraoka, Ryotaro Hayashi, Shinji Miyazaki, Tamio Furuse, Hiroaki Mizukami, Ryoichi Teruyama, Masaru Tamura and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Machi HoriaiDepartment of Molecular and Cell Biology, Graduate School of Agricultural Science, Tohoku University, 468-1 Aramaki-Aza-Aoba, Aoba-ku, Sendai, Miyagi, 980-0845, Japan.
Ayano OtsukaDepartment of Obesity and Internal Inflammation, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Shizu HidemaDepartment of Molecular and Cell Biology, Graduate School of Agricultural Science, Tohoku University, 468-1 Aramaki-Aza-Aoba, Aoba-ku, Sendai, Miyagi, 980-0845, Japan.
Yuichi HiraokaLaboratory for Molecular Neuroscience Medical Research Institute, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan.
Ryotaro HayashiDepartment of Molecular and Cell Biology, Graduate School of Agricultural Science, Tohoku University, 468-1 Aramaki-Aza-Aoba, Aoba-ku, Sendai, Miyagi, 980-0845, Japan.
Shinji MiyazakiDepartment of Molecular and Cell Biology, Graduate School of Agricultural Science, Tohoku University, 468-1 Aramaki-Aza-Aoba, Aoba-ku, Sendai, Miyagi, 980-0845, Japan.
Tamio FuruseTechnology and Development Team for Mouse Phenotype Analysis, Japan Mouse Clinic, RIKEN BioResouce Reserch Center (BRC), 3-1-1 Koyadai, Tsukuba, Ibaraki, 305-0074, Japan.
Hiroaki MizukamiDivision of Genetic Therapeutics, Center for Medicine, Jichi Medical University, Shimotsuke, Tochigi, 329-0498, Japan.
Ryoichi TeruyamaDepartment of Biological Sciences, Louisiana State University, Baton Rouge, LA, 70803, USA.ORCID 0000-0002-9356-8310
Masaru TamuraTechnology and Development Team for Mouse Phenotype Analysis, Japan Mouse Clinic, RIKEN BioResouce Reserch Center (BRC), 3-1-1 Koyadai, Tsukuba, Ibaraki, 305-0074, Japan.
Haruhiko BitoDepartment of Neurochemistry, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.ORCID 0000-0001-6315-9594
Yuko MaejimaDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Kenju ShimomuraDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Katsuhiko NishimoriDepartment of Molecular and Cell Biology, Graduate School of Agricultural Science, Tohoku University, 468-1 Aramaki-Aza-Aoba, Aoba-ku, Sendai, Miyagi, 980-0845, Japan. knishimo@fmu.ac.jp.
Fukushima Medical University · JPTohoku University · JPRIKEN BioResource Research Center · JPJichi Medical University · JPLouisiana State University · USThe University of Tokyo · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism spectrum disorder (ASD) is a continuum of neurodevelopmental disorders and needs new therapeutic approaches. Recently, oxytocin (OXT) showed potential as the first anti-ASD drug. Many reports have described the efficacy of intranasal OXT therapy to improve the core symptoms of patients with ASD; however, the underlying neurobiological mechanism remains unknown. The OXT/oxytocin receptor (OXTR) system, through the lateral septum (LS), contributes to social behavior, which is disrupted in ASD. Therefore, we selectively express hM3Dq in OXTR-expressing (OXTR+) neurons in the LS to investigate this effect in ASD mouse models developed by environmental and genetic cues. In mice that received valproic acid (environmental cue), we demonstrated successful recovery of impaired social memory with three-chamber test after OXTR+ neuron activation in the LS. Application of a similar strategy to Nl3

Indexed as

Gene ExpressionSocial BehaviorAnimalsAnxietyAutism Spectrum DisorderBehavior, AnimalDisease Models, AnimalFluorescent Antibody TechniqueMiceMice, KnockoutMolecular Targeted TherapyNeuronsPyramidal CellsReceptors, OxytocinSeptum of BrainReceptors, Oxytocin

Identifiers

PMID33335150
PMCPMC7746761
OpenAlexW3113049055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.